

Dawn C Buse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2980612/publications.pdf>

Version: 2024-02-01

162
papers

9,714
citations

34076

52
h-index

43868

91
g-index

167
all docs

167
docs citations

167
times ranked

4438
citing authors

#	ARTICLE	IF	CITATIONS
1	Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study. <i>Cephalalgia</i> , 2022, 42, 20-30.	1.8	9
2	Comorbidities in children and adolescents. , 2022, , 79-99.		1
3	Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. <i>Headache</i> , 2022, 62, 122-140.	1.8	43
4	Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials. <i>Headache</i> , 2022, 62, 159-168.	1.8	1
5	Combining Guided Intervention of Education and Relaxation (GIER) with Remote Electrical Neuromodulation (REN) in the Acute Treatment of Migraine. <i>Pain Medicine</i> , 2022, 23, 1544-1549.	0.9	6
6	Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2. <i>Clinical Therapeutics</i> , 2022, 44, 389-402.	1.1	10
7	Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. <i>Journal of Headache and Pain</i> , 2022, 23, 22.	2.5	7
8	Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine. <i>Journal of Headache and Pain</i> , 2022, 23, 29.	2.5	9
9	Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention. <i>Headache</i> , 2022, 62, 690-699.	1.8	6
10	Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2022, 62, 755-765.	1.8	5
11	The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210959.	1.5	4
12	Photophobia: shared pathophysiology underlying dry eye disease, migraine and traumatic brain injury leading to central neuroplasticity of the trigeminothalamic pathway. <i>British Journal of Ophthalmology</i> , 2021, 105, 751-760.	2.1	32
13	Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data. <i>Headache</i> , 2021, 61, 90-102.	1.8	14
14	Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2021, 61, 103-116.	1.8	10
15	Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. <i>Headache</i> , 2021, 61, 590-602.	1.8	12
16	Systematic review of outcomes and endpoints in acute migraine clinical trials. <i>Headache</i> , 2021, 61, 263-275.	1.8	33
17	Tension-type headache. <i>Nature Reviews Disease Primers</i> , 2021, 7, 24.	18.1	75
18	Migraine: epidemiology and systems of care. <i>Lancet</i> , The, 2021, 397, 1485-1495.	6.3	310

#	ARTICLE	IF	CITATIONS
19	Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. <i>Headache</i> , 2021, 61, 628-641.	1.8	35
20	Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. <i>Headache</i> , 2021, 61, 662-672.	1.8	27
21	Migraine: integrated approaches to clinical management and emerging treatments. <i>Lancet</i> , The, 2021, 397, 1505-1518.	6.3	139
22	Updated process for American Headache Society Guidelines. <i>Headache</i> , 2021, 61, 565-566.	1.8	0
23	Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. <i>Cephalalgia</i> , 2021, 41, 1152-1160.	1.8	10
24	Learning the full impact of migraine through patient voices: A qualitative study. <i>Headache</i> , 2021, 61, 1004-1020.	1.8	24
25	The value of the patient perspective in understanding the full burden of migraine. <i>Headache</i> , 2021, 61, 985-987.	1.8	1
26	Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine preventive medications in the phase 3b FOCUS study. <i>Headache</i> , 2021, 61, 1376-1386.	1.8	8
27	Health-related quality of life in tension-type headache: a population-based study. <i>Scandinavian Journal of Pain</i> , 2021, 21, 778-787.	0.5	12
28	Medication Overuse and Headache Burden. <i>Neurology: Clinical Practice</i> , 2021, 11, 216-226.	0.8	25
29	The migraine signature study: Methods and baseline results. <i>Headache</i> , 2021, 61, 462-484.	1.8	7
30	Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic Migraine. <i>Neurology: Clinical Practice</i> , 2021, 11, 194-205.	0.8	6
31	Is there a causal relationship between stress and migraine? Current evidence and implications for management. <i>Journal of Headache and Pain</i> , 2021, 22, 155.	2.5	29
32	Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 132.	0.9	3
33	Individuals with migraine have a different dry eye symptom profile than individuals without migraine. <i>British Journal of Ophthalmology</i> , 2020, 104, 260-264.	2.1	21
34	Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database. <i>Current Medical Research and Opinion</i> , 2020, 36, 51-61.	0.9	6
35	Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. <i>Cephalalgia</i> , 2020, 40, 503-516.	1.8	43
36	Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. <i>Headache</i> , 2020, 60, 416-429.	1.8	61

#	ARTICLE	IF	CITATIONS
37	Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2020, 60, 2340-2356.	1.8	47
38	Efficacy and Feasibility of Behavioral Treatments for Migraine, Headache, and Pain in the Acute Care Setting. <i>Current Pain and Headache Reports</i> , 2020, 24, 66.	1.3	10
39	Burden of Illness Among People with Migraine and ≈ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1334-1343.	0.5	22
40	Predicting the Future of Migraine Attack Prediction. <i>Headache</i> , 2020, 60, 2125-2128.	1.8	4
41	The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2020, 60, 1683-1696.	1.8	42
42	Ten Eleven Things Not to Say to Healthcare Professionals During the Coronavirus Disease 2019 Pandemic. <i>Headache</i> , 2020, 60, 1837-1845.	1.8	5
43	Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. <i>Neurology</i> , 2020, 95, e878-e888.	1.5	20
44	Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. <i>Journal of Headache and Pain</i> , 2020, 21, 109.	2.5	12
45	United States Patients'™ Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey. <i>Headache</i> , 2020, 60, 1351-1364.	1.8	23
46	Characterizing opioid use in a US population with migraine. <i>Neurology</i> , 2020, 95, e457-e468.	1.5	48
47	The prevalence of hypnic headache in Iceland. <i>Cephalalgia</i> , 2020, 40, 863-865.	1.8	8
48	Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. <i>Journal of Headache and Pain</i> , 2020, 21, 23.	2.5	143
49	Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. <i>Journal of Headache and Pain</i> , 2020, 21, 20.	2.5	35
50	Characterization of Acute Prescription Migraine Medication Use. <i>Mayo Clinic Proceedings</i> , 2020, 95, 709-718.	1.4	14
51	Author response: Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study. <i>Neurology</i> , 2020, 95, 707-708.	1.5	0
52	Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine. <i>Journal of Family Practice</i> , 2020, 69, S1-S7.	0.2	0
53	Epidemiology of migraine in men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Cephalalgia</i> , 2019, 39, 296-305.	1.8	34
54	Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2019, 59, 1286-1299.	1.8	135

#	ARTICLE	IF	CITATIONS
55	Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2019, 59, 1310-1323.	1.8	54
56	Migraine Progression: A Systematic Review. An Editorial Comment. <i>Headache</i> , 2019, 59, 974-976.	1.8	3
57	The Association Between Parental Migraine and Infant Colic: A Cross-sectional, Web-based, U.S. Survey Study. <i>Headache</i> , 2019, 59, 988-1001.	1.8	14
58	Migraine. <i>Neurologic Clinics</i> , 2019, 37, 631-649.	0.8	358
59	Behavioral Interventions for Migraine. <i>Neurologic Clinics</i> , 2019, 37, 789-813.	0.8	41
60	Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2019, 59, 1762-1772.	1.8	31
61	Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial. <i>Headache</i> , 2019, 59, 1448-1467.	1.8	62
62	Optimism, Pessimism, and Migraine: A Cross-sectional, Population-based Study. <i>Headache</i> , 2019, 59, 205-214.	1.8	10
63	Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ). <i>Headache</i> , 2019, 59, 1253-1269.	1.8	17
64	Evaluating Mean Level and Within-person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial. <i>Headache</i> , 2019, 59, 1002-1013.	1.8	7
65	Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study. <i>Cephalalgia</i> , 2019, 39, 873-882.	1.8	26
66	Migraine progression in subgroups of migraine based on comorbidities. <i>Neurology</i> , 2019, 93, e2224-e2236.	1.5	60
67	Migraine Progression: A Systematic Review. <i>Headache</i> , 2019, 59, 306-338.	1.8	198
68	Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 353-360.	0.9	47
69	Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2019, 59, 32-45.	1.8	63
70	When Mom Has Migraine: An Observational Study of the Impact of Parental Migraine on Adolescent Children. <i>Headache</i> , 2019, 59, 224-234.	1.8	12
71	Adolescent Perspectives on the Burden of a Parent's Migraine: Results from the CaMEO Study. <i>Headache</i> , 2018, 58, 512-524.	1.8	16
72	AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial. <i>Headache</i> , 2018, 58, 229-242.	1.8	10

#	ARTICLE	IF	CITATIONS
73	Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine Tracker. <i>Headache</i> , 2018, 58, 1358-1372.	1.8	25
74	Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ). <i>Headache</i> , 2018, 58, 1612-1628.	1.8	16
75	Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. <i>Headache</i> , 2018, 58, 1408-1426.	1.8	106
76	Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2018, 58, 933-947.	1.8	61
77	Assessing Physician–Patient Dialogues About Chronic Migraine During Routine Office Visits. <i>Headache</i> , 2018, 58, 993-1006.	1.8	9
78	Sex and Gender Differences in Migraine – Evaluating Knowledge Gaps. <i>Journal of Women's Health</i> , 2018, 27, 965-973.	1.5	38
79	Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. <i>Cephalalgia</i> , 2018, 38, 1622-1631.	1.8	59
80	Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. <i>Journal of Headache and Pain</i> , 2018, 19, 38.	2.5	88
81	Acceptance, Psychiatric Symptoms, and Migraine Disability: An Observational Study in a Headache Center. <i>Headache</i> , 2018, 58, 859-872.	1.8	11
82	Psychological Factors Associated With Chronic Migraine and Severe Migraine–Related Disability: An Observational Study in a Tertiary Headache Center. <i>Headache</i> , 2017, 57, 593-604.	1.8	71
83	Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale. <i>Headache</i> , 2017, 57, 570-585.	1.8	30
84	Framingham–Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2017, 57, 1507-1521.	1.8	51
85	Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary. <i>Headache</i> , 2017, 57, 1385-1398.	1.8	35
86	Faster Improvement in Migraine Pain Intensity and Migraine–Related Disability at Early Time Points with AVP–825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study. <i>Headache</i> , 2017, 57, 1570-1582.	1.8	12
87	Why Migraine Forecasting Matters. <i>Headache</i> , 2017, 57, 1023-1025.	1.8	8
88	Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa. <i>Current Pain and Headache Reports</i> , 2017, 21, 49.	1.3	77
89	Comorbid pain and migraine chronicity. <i>Neurology</i> , 2017, 89, 461-468.	1.5	61
90	Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2017, 57, 1026-1040.	1.8	49

#	ARTICLE	IF	CITATIONS
91	Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2017, 57, 31-44.	1.8	49
92	Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID). <i>Health and Quality of Life Outcomes</i> , 2017, 15, 224.	1.0	29
93	Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. <i>Journal of Headache and Pain</i> , 2017, 18, 101.	2.5	158
94	Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. <i>Mayo Clinic Proceedings</i> , 2016, 91, 596-611.	1.4	123
95	Childhood Maltreatment in the Migraine Patient. <i>Current Treatment Options in Neurology</i> , 2016, 18, 31.	0.7	15
96	Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2016, 56, 1635-1648.	1.8	64
97	A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability. <i>Headache</i> , 2016, 56, 1280-1289.	1.8	127
98	Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study. <i>Headache</i> , 2016, 56, 118-131.	1.8	49
99	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2016, 56, 821-834.	1.8	160
100	Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2016, 56, 292-305.	1.8	73
101	2015 <i>Headache</i> Members' Choice Award. <i>Headache</i> , 2016, 56, 1088-1090.	1.8	0
102	Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 143.	1.0	55
103	Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey. <i>Headache</i> , 2016, 56, 306-322.	1.8	147
104	Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). <i>Cephalalgia</i> , 2016, 36, 203-215.	1.8	42
105	Ecological momentary assessment of the relationship between headache pain intensity and pain interference in women with migraine and obesity. <i>Cephalalgia</i> , 2016, 36, 1228-1237.	1.8	20
106	Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2015, 55, 825-839.	1.8	20
107	Clinical Pain Catastrophizing in Women With Migraine and Obesity. <i>Headache</i> , 2015, 55, 923-933.	1.8	54
108	Persistent Frequent Nausea Is Associated With Progression to Chronic Migraine: AMPP Study Results. <i>Headache</i> , 2015, 55, 76-87.	1.8	46

#	ARTICLE	IF	CITATIONS
109	Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. <i>International Journal of General Medicine</i> , 2015, 8, 79.	0.8	51
110	Burden of migraine related to menses: results from the AMPP study. <i>Journal of Headache and Pain</i> , 2015, 16, 24.	2.5	60
111	Recalled maltreatment, migraine, and tension-type headache. <i>Neurology</i> , 2015, 84, 132-140.	1.5	66
112	Primary headache: What's stress got to do with it?. <i>Cephalalgia</i> , 2015, 35, 844-849.	1.8	7
113	Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. <i>Neurology</i> , 2015, 84, 688-695.	1.5	219
114	Behavioral Treatments for Migraine Management: Useful at Each Step of Migraine Care. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 14.	2.0	31
115	Acute Treatment Optimization in Episodic and Chronic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2015, 55, 502-518.	1.8	32
116	The Biopsychosocial/Spiritual Impact of Chronic Pain, Chronic Illness, and Physical Disabilities in Adolescence. <i>Current Pain and Headache Reports</i> , 2015, 19, 51.	1.3	5
117	The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. <i>Cephalalgia</i> , 2015, 35, 563-578.	1.8	203
118	Methodological Issues in Studying Trigger Factors and Premonitory Features of Migraine. <i>Headache</i> , 2014, 54, 1661-1669.	1.8	84
119	Reduction in perceived stress as a migraine trigger. <i>Neurology</i> , 2014, 82, 1395-1401.	1.5	123
120	Trigger Factors and Premonitory Features of Migraine Attacks: Summary of Studies. <i>Headache</i> , 2014, 54, 1670-1679.	1.8	111
121	Chronic rhinitis and its association with headache frequency and disability in persons with migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Cephalalgia</i> , 2014, 34, 336-348.	1.8	34
122	Improving the Classification of Migraine Subtypes: An Empirical Approach Based on Factor Mixture Models in the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2014, 54, 830-849.	1.8	32
123	Impact of NSAID and Triptan Use on Developing Chronic Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2013, 53, 1548-1563.	1.8	53
124	Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Value in Health</i> , 2013, 16, 31-38.	0.1	99
125	Dating and Relationship Psychoeducational Group for Veterans with Spinal Cord Injury/Dysfunction: A Historical Account of an Initial Clinical Course. <i>Sexuality and Disability</i> , 2013, 31, 337-359.	0.4	7
126	Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2013, 53, 1278-1299.	1.8	330

#	ARTICLE	IF	CITATIONS
127	Headache-related health resource utilisation in chronic and episodic migraine across six countries. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1309-1317.	0.9	36
128	Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. <i>Journal of the Neurological Sciences</i> , 2013, 326, 10-17.	0.3	33
129	Barriers to the Diagnosis and Treatment of Migraine: Effects of Sex, Income, and Headache Features. <i>Headache</i> , 2013, 53, 81-92.	1.8	144
130	Frequency and Burden of Headache-Related Nausea: Results From the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2013, 53, 93-103.	1.8	59
131	Psychiatric comorbidities of episodic and chronic migraine. <i>Journal of Neurology</i> , 2013, 260, 1960-1969.	1.8	283
132	Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Journal of Medical Economics</i> , 2013, 16, 490-499.	1.0	13
133	The Headache Under-Response to Treatment (HURT) Questionnaire: Assessment of utility in headache specialist care. <i>Cephalalgia</i> , 2013, 33, 245-255.	1.8	24
134	Assessing the quality of health-related quality of life measures. <i>Cephalalgia</i> , 2013, 33, 223-225.	1.8	8
135	Global perspectives on the burden of episodic and chronic migraine. <i>Cephalalgia</i> , 2013, 33, 885-890.	1.8	38
136	Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2013, 53, 1300-1311.	1.8	128
137	Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans. <i>Headache</i> , 2013, 53, 1415-1429.	1.8	21
138	Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II). <i>Headache</i> , 2013, 53, 644-655.	1.8	295
139	Depression and risk of transformation of episodic to chronic migraine. <i>Journal of Headache and Pain</i> , 2012, 13, 615-624.	2.5	214
140	Why HURT? A Review of Clinical Instruments for Headache Management. <i>Current Pain and Headache Reports</i> , 2012, 16, 237-254.	1.3	59
141	Opioid Use and Dependence Among Persons With Migraine: Results of the AMPP Study. <i>Headache</i> , 2012, 52, 18-36.	1.8	103
142	Depression and Anxiety in Episodic and Chronic Cluster Headache: A Pilot Study. <i>Headache</i> , 2012, 52, 600-611.	1.8	39
143	Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2012, 52, 213-223.	1.8	25
144	Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2012, 52, 1456-1470.	1.8	389

#	ARTICLE	IF	CITATIONS
145	Defining the Differences Between Episodic Migraine and Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2012, 16, 86-92.	1.3	211
146	Longitudinal Change in Migraine Headache-Days and Indirect Cost Consequences. <i>Journal of Occupational and Environmental Medicine</i> , 2011, 53, 478-487.	0.9	11
147	A Case Study for Calculating Employer Costs for Lost Productive Time in Episodic Migraine and Chronic Migraine. <i>Journal of Occupational and Environmental Medicine</i> , 2011, 53, 1161-1171.	0.9	20
148	Cost of Health Care Among Patients With Chronic and Episodic Migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS). <i>Headache</i> , 2011, 51, 1058-1077.	1.8	204
149	Nonpharmacologic Treatments for Migraine and Tension-Type Headache: How to Choose and When to Use. <i>Current Treatment Options in Neurology</i> , 2011, 13, 28-40.	0.7	76
150	Chronic Migraine: Epidemiology and Disease Burden. <i>Current Pain and Headache Reports</i> , 2011, 15, 70-78.	1.3	176
151	The International Burden of Migraine Study (IBMS): Study design, methodology, and baseline cohort characteristics. <i>Cephalalgia</i> , 2011, 31, 1116-1130.	1.8	59
152	Biobehavioral, Complementary and Alternative Treatments for Headache. , 2011, , 667-686.		2
153	Rates and Predictors of Starting a Triptan: Results From the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2010, 50, 1440-1448.	1.8	21
154	Employment and Work Impact of Chronic Migraine and Episodic Migraine. <i>Journal of Occupational and Environmental Medicine</i> , 2010, 52, 8-14.	0.9	148
155	Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life. <i>Mayo Clinic Proceedings</i> , 2009, 84, 422-435.	1.4	180
156	Behavioral medicine for migraine and medication overuse headache. <i>Current Pain and Headache Reports</i> , 2009, 13, 241-248.	1.3	33
157	Behavioral Medicine for Migraine. <i>Neurologic Clinics</i> , 2009, 27, 445-465.	0.8	96
158	Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life. <i>Mayo Clinic Proceedings</i> , 2009, 84, 422-435.	1.4	134
159	Facilitating communication with patients for improved migraine outcomes. <i>Current Pain and Headache Reports</i> , 2008, 12, 230-236.	1.3	39
160	Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 636-649.	0.7	81
161	Headache and Combination Estrogen-Progestin Oral Contraceptives: Integrating Evidence, Guidelines, and Clinical Practice. <i>Headache</i> , 2005, 45, 224-231.	1.8	43
162	Epidemiology of the psychiatric comorbidities of headache. , 0, , 1-8.		0